Hsp90 Blockade als therapeutischer Ansatz zur Modulation von Tumormetabolismus und -angiogenese in gastrointestinalen Karzinomen

• Antragsteller: Professor Dr. Sven Arke Lang
• Fachliche Zuordnung: Hämatologie, Onkologie
• Förderung: Förderung von 2011 bis 2014
• Projektkennung: Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 190230491

• Erstellungsjahr: 2019

Zusammenfassung der Projektergebnisse

Results from our experiments showed novel insights into the effects of Hsp90 blockade on cancer metabolism with special emphasis on HK II in cancer cells. Although Hsp90 blockade did not affect angiogenesis in the FGF/FGFR system as we suggested, we assessed the efficacy of targeting the FGFR system in several cancer models, including the effects on angiogenesis and tumor stroma. Finally, we determined STAT5b as a novel target on human pancreatic cancer via effects on metabolism and angiogenesis.

Projektbezogene Publikationen (Auswahl)

• 2011. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Molecular Cancer Therapeutics 10: 2157-2167
  Taeger, J., C. Moser, C. Hellerbrand, M. E. Mycielska, G. Glockzin, H. J. Schlitt, E. K. Geissler, O. Stoeltzing, and S. A. Lang
  
• (2012) Contrast-enhance ultrasound (CEUS) detects effects of vascular disrupting therapy in an experimental model of gastric cancer. Clinical hemorheology and microcirculation. Clin Hemorheol Microcirc.
  Lang, S. A., C. Moser, S. Gehmert, K. Pfister, C. Hackl, A. A. Schnitzbauer, C. Stroszczynski, H. J. Schlitt, E. K. Geissler, and E. M. Jung
  
• (2012) STAT5b as molecular target in pancreatic cancer--inhibition of tumor growth, angiogenesis, and metastases. Neoplasia 14: 915-925
  Moser, C., P. Ruemmele, S. Gehmert, H. Schenk, M. P. Kreutz, M. E. Mycielska, C. Hackl, A. Kroemer, A. A. Schnitzbauer, O. Stoeltzing, H. J. Schlitt, E. K. Geissler, and S. A. Lang
  
• (2012) Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer. Anticancer Research 32: 2551-2561
  Moser, C., S. A. Lang, C. Hackl, C. Wagner, E. Scheiffert, H. J. Schlitt, E. K. Geissler, and O. Stoeltzing
  
• 2012. Oncogenic MST1R activity in pancreatic and gastric cancer represents a valid target of HSP90 inhibitors. Anticancer Research 32: 427-437
  Moser, C., S. A. Lang, C. Hackl, H. Zhang, K. Lundgren, V. Hong, A. McKenzie, B. Weber, J. S. Park, H. J. Schlitt, E. K. Geissler, Y. D. Jung, and O. Stoeltzing